FibroBiologics Common Stock Statistics
Share Statistics
FibroBiologics Common Stock has 34.66M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 34.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 2.05K |
| FTD / Avg. Volume | 0.89% |
Short Selling Information
The latest short interest is 2.36M, so 6.71% of the outstanding shares have been sold short.
| Short Interest | 2.36M |
| Short % of Shares Out | 6.71% |
| Short % of Float | 8.79% |
| Short Ratio (days to cover) | 15.94 |
Valuation Ratios
The PE ratio is -57.36 and the forward PE ratio is -8.81.
| PE Ratio | -57.36 |
| Forward PE | -8.81 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 754.6 |
| P/FCF Ratio | -137.11 |
| PEG Ratio | n/a |
Enterprise Valuation
FibroBiologics Inc. Common Stock has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1, with a Debt / Equity ratio of 0.
| Current Ratio | 1 |
| Quick Ratio | 1 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -60.47 |
Financial Efficiency
Return on equity (ROE) is -13.16% and return on capital (ROIC) is -296.3%.
| Return on Equity (ROE) | -13.16% |
| Return on Assets (ROA) | -1.39% |
| Return on Capital (ROIC) | -296.3% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.65M |
| Employee Count | 10 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so FibroBiologics Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 2.79 |
| 200-Day Moving Average | 5.91 |
| Relative Strength Index (RSI) | 38.31 |
| Average Volume (20 Days) | 231.41K |
Income Statement
In the last 12 months, FibroBiologics Common Stock had revenue of $0 and earned -$16.48M in profits. Earnings per share was $-0.59.
| Revenue | 0 |
| Gross Profit | -437.00K |
| Operating Income | -8.89M |
| Net Income | -16.48M |
| EBITDA | -15.90M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.59 |
Balance Sheet
The company has $9.16M in cash and $1.75M in debt, giving a net cash position of $7.42M.
| Cash & Cash Equivalents | 9.16M |
| Total Debt | 1.75M |
| Net Cash | 7.42M |
| Retained Earnings | -24.36M |
| Total Assets | 10.47M |
| Working Capital | 1.52M |
Cash Flow
In the last 12 months, operating cash flow was -$6.40M and capital expenditures -$495.00K, giving a free cash flow of -$6.90M.
| Operating Cash Flow | -6.40M |
| Capital Expenditures | -495.00K |
| Free Cash Flow | -6.90M |
| FCF Per Share | -0.21 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
FBLG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -26.94% |
| FCF Yield | -9.09% |
Analyst Forecast
The average price target for FBLG is $12, which is 447.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 447.9% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -3.66 |
| Piotroski F-Score | 1 |